Clinical trials
Muscular Diseases trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Recruiting | 5 |
| Active, not recruiting | 4 |
| Terminated | 3 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Barts & The London NHS Trust | 2 |
| Calcilytix Therapeutics, Inc., a BridgeBio company | 2 |
| Guy's and St Thomas' NHS Foundation Trust | 2 |
| Novartis Pharmaceuticals | 2 |
| PTC Therapeutics | 2 |
| Stealth BioTherapeutics Inc. | 2 |
| Vertex Pharmaceuticals Incorporated | 2 |
| Abcuro, Inc. | 1 |
| AstraZeneca | 1 |
| Avidity Biosciences, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Muscular Diseases | 25 |
| Musculoskeletal Diseases | 12 |
| Nervous System Diseases | 9 |
| Neuromuscular Diseases | 9 |
| Genetic Diseases, Inborn | 7 |
| Muscular Disorders, Atrophic | 7 |
| Muscular Dystrophies | 7 |
| Muscular Dystrophy, Duchenne | 4 |
| Myotonic Dystrophy | 4 |
| Genetic Diseases, X-Linked | 3 |
Trials
Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.